Project Grant 2036538

This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...

This National Science Foundation (NSF) Cooperative Agreement award, provided through the NSF Technology, Innovation, and Partnerships (CFDA #47.084) program, funds the development of a novel, fully implantable craniofacial distraction system by Ostiio LLC, a medical device company based in Philadelphia, PA. The $1,000,000 award aims to produce a magnetic, subcutaneous distraction device capable of gradually correcting skeletal abnormalities affecting craniomaxillofacial functions such as...

Federal Grant Award Summary Safeguard Surgical, Inc. received $813,000 in Small Business Innovation Research (SBIR) Phase I funding from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 18, 2025, with a completion date of August 31, 2026. The company is developing LeakGuard, a biodegradable barrier device designed to prevent anastomotic leakage (AL)—a serious complication affecting up to 22% of esophageal cancer patients undergoing...

Sentire Medical Systems, Inc. was awarded a $256,000 National Science Foundation Project Grant to develop an intraoperative monitoring device to detect bowel injuries during laparoscopic surgical procedures. The goal of the NSF Technology, Innovation, and Partnerships program is to advance science and engineering research leading to breakthrough technologies that address national challenges. Through this award, Sentire Medical will characterize gases present during laparoscopic surgery to...

Federal Grant Award Summary Endonavis LLC received a $226,192 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on July 15, 2025, with a completion date of June 30, 2026. The company is developing a novel over-the-scope platform designed to control variceal bleeding—a life-threatening complication in cirrhotic patients with mortality rates reaching...

This National Science Foundation Technology, Innovation, and Partnerships grant award of $250,000 provides funding from August 15, 2022 to July 31, 2024 to develop and evaluate an absorbable surgical adhesive patch to reinforce internal suture lines in the urinary tract. The University of California, Los Angeles will receive the award to create a flexible, bioabsorbable internal suture reinforcement device aimed at significantly reducing post-operative complications and readmissions for...

Grant Award Summary In Vivo Microsystems Technologies, LLC received a Phase 2 Small Business Innovation Research (SBIR) award of $2,044,110 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, issued on September 19, 2025, and concluding August 31, 2027, supports a multi-center clinical study to advance a near-infrared fluorescently-labeled peptide heterodimer...

This STTR Phase I Project Grant, awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program), provides $305,000 to Magsorbeo Biomedical Corp to develop a bioabsorbable magnesium alloy for maxillofacial fixation implants. The goal is to create a magnesium-based implant that can temporarily support healing, then gradually be absorbed by the body, eliminating the need for secondary removal surgeries. This innovation aims to improve healthcare...

This $999,783 Phase II Small Business Innovation Research (SBIR) cooperative agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Intact Therapeutics' development of a thermogel-based drug delivery platform for the treatment of upper gastrointestinal bleeding (UGIB). Intact Therapeutics' proprietary thermogel technology aims to rapidly stop UGIB prior to endoscopic treatment, potentially reducing patient morbidity,...

This $274,547 Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel Aneurysm Sealing Device (ASD) for endovascular treatment of Abdominal Aortic Aneurysms (AAA). The project seeks to create a device that can completely seal the aneurysm sac, reducing the risk of post-procedure complications and the need for repeat interventions. Key objectives include validating the device's adaptability...